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Abstract 
 
The activation of protooncogenes and inactivation of tumor suppressor genes are considered 
to be the main molecular events in the multistep process of carcinogenesis. Mutations of the 
TP53 tumor suppressor gene have been found in nearly all tumor types and are estimated to 
contribute to more than 50% of all cancers. Most mutations lead to the synthesis of highly 
stable, inactive proteins that accumulate in the nucleus of cancer cells. Among the 393 codons 
of the human p53 gene, 222 are targets of 698 different types of mutations. Alterations of 
codons 175, 248, 273 and 282 correspond to 19 % of all mutations and are considered general 
hot spot mutations. Dietary exposure to aristolochic acid (AA), an established nephrotoxin 
and human carcinogen found in all Aristolochia species was shown to be the causative agent 
of aristolochic acid nephropathy (previously called Chinese herbs nephropathy). This 
syndrome is characterized by proximal tubular damage, renal interstitial fibrosis, slow 
progression to the end stage renal disease and a high prevalence of upper urinary tract 
urothelial carcinoma (otherwise a highly unusual location). AA preferentially binds to purines 
in DNA and is associated with a high frequency of A → T transversions in the p53 gene. Rats 
treated with AA develop A:T → T:A mutations in codon 61. The pathological and clinical 
features of endemic (Balkan) nephropathy closely resemble those associated with aristolochic 
acid nephropathy except for the slower progression to end stage renal disease and 
longer cumulative period before the appearance of urothelial cancer. Recently, we 
reported the presence of AA-DNA adducts in renal cortex and A → T p53 mutations in tumor 
tissue of patients from Croatia and Bosnia with endemic nephropathy. These data support the 
hypothesis that dietary exposure to AA is a major risk factor for endemic (Balkan) 
nephropathy.   
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Introduction 
A principal objective of cancer research is to understand the etiology of 
environmentally induced malignancies, with the long-term objective of goal of 
reducing the incidence of human cancer. The most common cancer-related genetic 
changes in humans are mutations within the p53 gene. TP53 is a tumor suppressor 
gene that governs cellular responses to a broad spectrum of stress (DNA damage, 
hypoxia, oncogenic stress) by inducing transient or permanent cell cycle arrest or 
apoptosis and plays a key role in the prevention of cancer development.  
Both exogenous exposure to carcinogens and endogenous biological processes are 
known to cause mutations in DNA. Chemical carcinogens induce mutations by 
forming covalent adducts with the nucleotides in DNA, increasing the probability of 
enzymatic errors during DNA replication (1). Studies have shown that some 
carcinogenic agents produce a specific mutational pattern, a “DNA fingerprint” (2), 
because specific types and locations of DNA adducts are linked to a specific 
mutational spectrum in a DNA sequence (3). The mutational spectra of cancer-related 
genes differ depending on cancer type, but provide a molecular link between cancer 
and etiological agent, and give clues to the nature of carcinogens responsible for 
genetic alterations (4).  
Specifically, the study of mutational spectra of p53 and other important cancer-related 
genes can give us clues about carcinogen-DNA interactions, functions of gene 
products and mechanisms of carcinogenesis in specific tissues (3). The p53 gene is a 
good choice for mutational spectrum analysis for several reasons. First, p53 mutations 
are the single most frequent in human tumors and are directly involved in cancer 
formation (more than 20, 000 occurrences of human p53 mutations have been 
registered to date in the International Tumor Registry IARC p53 database 
(http://www-p53.iarc.fr) (5). Second, the p53 gene is relatively small (11 exons 
coding for 393 amino acids), permitting the mutational study of the entire coding 
region (6,7). p53 is highly conserved throughout vertebrates, allowing data 
comparison in animals. Third, most mutations fall into the DNA binding domain 
(DBD), responsible for sequence-specific DNA binding and transcriptional activity, 
as well as for a direct mitochondrial pro-apoptotic activity.  
Many studies have demonstrated a significant correlation between p53 mutational 
spectra and exposure to various types of carcinogens. Mutational hotspots at CpG 
dinucleotides in codons 175, 248, 249, 273 and 282 reflect an endogenous mutagenic 
mechanism (8).  On the other hand, G:C → T:A (G → T) transversions, the most 
frequent substitutions in human cancers, are likely to be caused by carcinogen-DNA 
adducts, and are more frequent in lung cancers of smokers compared to lung cancers 
of nonsmokers (8). Cigarette smoking has been established as a major risk factor for 
the incidence of lung cancer, and p53 mutational hotspots are codons 157, 158, 248, 
249 and 273. Codon 157, G → T transversions, one of the hotspots in lung, breast, 
and head and neck cancers, is uncommon in other types of cancer, and is associated 
with smoking in lung cancer patients. Moreover, the proof for causality became solid 
when it was shown that in vitro exposure of bronchoepithelial and HeLa cells to 
tobacco-derived benzo(a)pyrene generates strong and selective adduct formation at 
guanine positions in codons 157, 248, and 273 (9). Similar benzo(a)pyrene data was 
later shown e.g. for hotspots of liver cell carcinoma. 
In liver tumors from populations living in endemic areas where aflatoxin B1 and 
hepatitis B virus are risk factors for hepatocellular carcinoma, most p53 mutations 
occur at the third nucleotide position (AGG to AGT) of codon 249ser (10,11,12). The 
249ser p53 mutant is more effective in inhibiting wild-type (wt) p53 transcriptional 
activity in human liver cells than other p53 mutants (143ala, 175his, 248trp and 282his) 
(13). 
Another association between p53 mutational spectra and carcinogen exposure was 
found in skin carcinoma caused by UV irradiation – p53 mutations are located at 
dipyrimidine sites, generating CC → TT double-base transitions (14). Furthermore, 
the p53 mutational pattern in radon-associated lung cancer from uranium miners 
differs from the one in lung cancer caused by smoking alone (15). Moreover, liver 
angiosarcomas of vinyl chloride-exposed factory workers have higher frequency of 
p53 A:T → T:A transversions comparing to sporadic angiosarcoma (16).  
In summary, these differences in mutational frequency and spectra among human 
cancer types may be traced to exogenous and endogenous factors to human 
carcinogenesis (17).  
 
Aristolochic acid  
Aristolochic acid (AA) is an intrinsic component of Aristolochia sp. (Aristolochia 
clematitis, A. fanghi, etc.). The structurally related aristolochic acid I (AA-I) and 
aristolochic acid II (AA-II) are nitrophenanthrene carboxylic acids. Herbal medicines 
derived from Aristolochia have been used since ancient times to treat disease (18). 
However, in the 1980s AA was shown to be a strong carcinogen in rats and, in short-
term tests, to be a genotoxic mutagen (19,20,21,22). The US Food and Drug 
Administration (FDA) has issued warnings regarding the medicinal use of 
Aristolochia herbals. Nevertheless, Aristolochia is still widely used in traditional 
medicines and so called “natural” remedies.  
AA is metabolized and activated in a living organism through two major metabolic 
pathways: (i) demethylation of AA I by cytochrome P450 generates a non-
nephrotoxic product, that is biotransformed to glucuronide or sulphate conjugates 
(23); (ii) reactions catalyzed by cellular nitroreductases (such as NADP(H), 
quinonoxidoreductase (NQO1), xanthine oxidase (XO), CYP1A1 and CYP1A2) 
generate reactive intermediate cyclic nitrenium ion (24,25). This electrophilic 
intermediate subsequently reacts with proteins and DNA, the latter leading to gene 
mutation and induction of tumors (26,27). The activation of AA takes place mainly in 
the liver and kidneys, targeting the kidney (cytotoxicity) and forestomach (cancer) in 
rodents (28).  
The herbal drugs containing Aristolochia have been associated with development of a 
characteristic chronic interstitial nephropathy associated with proximal tubular 
damage and severe interstitial fibrosis starting from cortex with paucy cellular 
infiltratates sparing glomeruli called aristolochic acid nephropathy (AAN). This 
tubulointerstitial kidney disease is associated with urothelial carcinoma of the renal 
pelvis and upper ureter (29,30). This location is highly unusual as sporadic urothelial 
carcinoma occurs mostly in the lower urinary tract, typically the bladder. Urothelial 
cancers in the Western world at large occur in the bladder, ureter and renal pelvis at a 
ratio of 50:3:1. Thus, upper urinary tract cancers are uncommon and typically 
associated with particular exogenous carcinogens. (31). Atypia of urothelial cells 
throughout the renal tubules, pelvis and ureter are commonly reported in AAN (29). 
About one hundred AAN cases have been identified so far in Belgium among women 
undergoing a slimming treatment involving ingestion of A. fangchi that was 
inadvertently put into the slimming pills for several months (29,32,33). Additional 
AAN cases have been identified in Europe, Asia and the US. Subsequently, 
approximately 40%-46% of AAN patients developed urothelial carcinoma in the renal 
pelvis and ureter within 2-6 years either as non-invasive urothelial cancer (papillary 
carcinoma) or as invasive flat urothelial carcinoma (30,34,35,36). Known risk factors 
for upper urothelial cancer are occupational exposure to aniline dyes, acrylamines and 
chemicals used in the rubber, leather and petrochemical industries, chronic analgesic 
abuse and chronic irritation (kidney stone). Cigarette smoking is a major risk factor 
for urothelial and squamous cell carcinoma at all sites. Patients with upper urothelial 
cancers in general have a 30-50% chance of developing subsequent bladder cancer 
(37). Very recently, occurrence of bladder cancer 15 years after kidney transplantation 
in AAN patients was reported (38). Bilateral nephrectomy was performed several 
years before bladder cancers were diagnosed, preventing the possibility that upper 
urothelial cancers could have been detected (38). 
 
AA as a mutagen 
AA forms covalent DNA adducts in rodents (40,41,42) as well as in AAN patients 
(36,43,44,45). Covalently bound AA-DNA adducts, present for the life time in 
rodents and for many years in humans, now are considered to be a reliable biomarker 
of exposure to this environmental carcinogen (25,27,44,45,46). 
The enzymatic activation of AA leads to formation of the ultimate carcinogen 
aristolactam-nitrium ion (cyclic N-acylnitrenium ion) (Figure 1), which binds to 
DNA, preferentially to exocyclic amino groups of purine nucleotides (deoxyadenosine 
and deoxyguanosine), forming 7-(deoxyadenosin-N(6)-yl)aristolactam I (dA-AAI, 
compound 2, Figure 1) and 7-(deoxyguanosin-N(2)-yl) aristolactam I (dG-AAI, 
compound 3, Figure 1), 7-(deoxyadenosin-N(6)-yl) aristolactam II (dA-AAII) and 7-
(deoxyguanosin-N(2)-yl) aristolactam II (dG-AAII). The activation of AA is an 
unusual case of intramolecular acylation, producing the ultimate carcinogen (27,39).  
The dominant and most persistent DNA adduct, dA-AAI, is a mutagenic lesion 
leading to AT → TA transversions in vitro. DNA binding studies confirmed that AAI 
and AAII bind to the adenines of mouse ras codon 61, forming adducts associated 
with distinct activation of H-ras by a specific A → T transversion at codon 61 (wt 
CAA → CTA). This mutation occurs selectively at the first adenine of codon 61 in all 
AA-induced squamous cell carcinomas of the forestomach and ear duct examined in 
rat (47,48). Similar mutations, but at lower frequency, were demonstrated at c-Ki-ras 
codon 61 in 1 of 7 ear duct tumors (CAA → CAT) and in 1 of 8 tumors of the small 
intestine (CAA → CTA), as well as at c-N-ras codon 61 (CAA → CTA) in a 
pancreatic metastasis (47). Of note, neither have other ras codons nor ras mutations in 
urothelial cancers been studied to date. 
Urothelial carcinoma as well as urothelial atypia have been associated with 
overexpression of p53 protein in urothelial atypia and neoplastic cells from 10/10 and 
4/4 Belgian AAN patients, respectively, suggesting that the p53 gene is mutated in 
AAN-associated urothelial carcinoma (29,34). Hollstein et al. (49) designed a 
powerful and elegant genetic mutagenesis assay that allows proofing the direct 
mutagenic effect of a test substance towards human p53 in primary tissue culture 
cells. Mouse embryo fibroblasts derived from gene-targeted knock-in mice (Hupki), 
that had substituted their endogenous mouse p53 DBD (Ex 4-9) by the human 
counterpart, were exposed to AAI (100 M for 48 h) and then subjected to 9-13 
passages. Five of the 10 established cultures harbored p53 DBD mutations that 
produced aberrant nuclear overexpression of the mutant protein. Of note, all were 
transversions, including 4 A → T transversions on the non-transcribed strand, a rather 
unique hallmark of mutagenesis by AAI (and rare in spontaneous mutations) (47,49). 
Moreover, the characteristic d-adenosine and d-guanosine DNA adducts of AAI were 
detected in the DNA of the outgrowing fibroblast lines (50). Remarkably, urothelial 
carcinoma cells from an AAN-patient in UK also harbored an A → T transversion 
(AAG → TAG) on the non-transcribed strand at codon 139 of exon 5 in the p53 gene, 
leading to a stop (Lys → Stop) (50). Moreover, the mutated base adenine has the 
same neighboring bases in codon 139 of the p53 gene as in codon 61 (CAA) of the H-
ras gene, suggesting a sequence specific mechanism during mutagenesis (50). 
Another mutation (G → A) was found in codon 245 (hotspot for p53 mutations) in the 
p53 gene in DNA from the breast and liver tumors of the same AAN patient (50). 
Since G → A transitions are not typical of AA, it is not likely that the p53 mutation in 
the breast and liver tumors was induced by AA and probably only the urothelial tumor 
was causally related to AA exposure. Importantly, this study provides a direct 
etiologic link between a defined exposure to a chemical carcinogen and human cancer 
and clear additional support for the carcinogenicity of AA.  
Recently, the same Hupki system was used for studies of the AA mutation signature 
in the human p53 gene. Six immortalized cultures from 18 primary cultures exposed 
to AAI (50 M for 48 h) again harbored p53 mutations in the human DNA binding 
domain. The most frequently observed mutation was A → T transversion (51). One of 
the mutations was identical to the A → T transversion in codon 139, originally seen in 
the urothelial cancer of an AAN patient with documented AAI exposure (50). In 
contrast, among the seven p53 mutations identified thus far in >60 Hupki cell lines 
that immortalized spontaneously (i.e. no carcinogen treatment), none were A:T → 
T:A transversions. In addition, no A → T substitutions were identified among the 
previously reported set of 18 mutations in Hupki cell lines derived from 
benzo(a)pyrene treatment, in which transversions at G → C base pairs predominated 
(51). Finally, using AAI and AAII-exposed DNA from the human breast cancer cell 
line, the AA-DNA binding spectrum within the p53 gene was mapped preferentially 
to purines in Exons 5-8 of p53 (52).  
The relationship between AA-induced DNA adducts and mutations in rat liver and 
kidney (the tissues that activate AA) was recently reported by Mei et al. (28). Strong 
linear dose-responses for AA-induced DNA adducts were found in treated rats.. 
Kidneys had at least two-fold higher levels of DNA adducts and mutation frequencies 
than livers, with no significant difference between the mutation spectra in AA-treated 
livers and kidneys (mostly A:T → T:A transversions). However, there was a 
significant difference between the mutation spectra in both kidney and liver of AA-
treated and control rats (mostly G:C → A:T transitions). These results link AA 
exposure that eventually results in kidney tumors in rats, to a significant increase in 
AA-induced DNA adduct formation with a characteristic mutation in kidney tissue. 
Although the same treatment does not produce tumors in rat liver, it does induce DNA 
adducts and mutations in this tissue, albeit at lower levels than in the kidney (28). 
Moreover, the mutation frequency in kidneys of AA-treated rats was shown to 
correlate with tumor incidence in the kidney (53).  
 
Aristolochic acid nephropathy and endemic (Balkan) nephropathy 
Endemic nephropathy (EN) is characterized by chronic tubulointerstitial nephritis 
with slow progression to terminal renal failure. EN is present in several rural areas in 
the valleys of big Danube tributaries in Bosnia and Herzegovina, Bulgaria, Croatia, 
Romania and Serbia affecting approximately 2-7% of exposed rural farming 
population (54,55). EN has several epidemiological characteristics: (i) it is present 
only in certain villages with completely unaffected villages located in close 
proximity; (ii) household (not inherited) pattern of disease was observed; (iii) it 
affects only adult population; (iv) there is strong association (~30-50%) with upper 
urothelial cancers (UUC). The specific mortality associated with UUC in this region 
is 50 times higher than elsewhere in Europe (56). Epidemiologic findings and striking 
geographical correlation of two very rare diseases pointed from the beginning to a 
common environmental etiological agent. EN was first described more than 50 years 
ago and many toxic agents have been investigated (57). In the last two decades 
ochratoxin A (OTA) was a major focus of interest. This hypothesis was supported by 
the detection of so-called “OTA-associated” DNA adducts (deoxyguanosin adducts) 
in urothelial tumors of Bulgarian patients (58). However, presence of OTA in these 
adducts could not be confirmed (59,60). Although there are reports on higher 
concentrations of OTA in food, blood and urine of inhabitants in EN regions 
compared to other regions, there is no evidence that OTA is a risk factor for EN (61, 
62). According to the European branch of the International Life Sciences Institutes, 
there is no convincing evidence from human epidemiology to confirm the association 
between OTA exposure and the prevalence of EN and/or upper urothelial cancers 
(63). The Scientific Panel on Contaminants in the Food Chain of the European Food 
Safety Authority also concluded that epidemiological data are incomplete and do not 
justify the classification of OTA as a human renal carcinogen (64). OTA induces renal 
adenomas in rodents and no urothelial cancers. This is one of the strongest arguments 
against OTA as a major risk factor for EN-associated urothelial malignancy.  
Pathological findings in EN differ also in some very important elements from findings 
in animal models of OTA nephrotoxicity but are almost identical with findings in 
aristolochic acid nephropathy (30).  
Vanherweghem and his group (33) suggested that the hypothesis that AA was an 
etiologic agent in EN should be evaluated. Based on pathological findings, Cosyns et 
al. (30) debate whether AAN could be the clue for EN, caused by the common 
etiologic agent, AA. More than 30 years ago Ivić (65) made remarkable observations 
that implicated AA as a major risk factor for EN. Unfortunately, during the next three 
decades, this hypothesis was put aside, and we confirmed (66) for the first time 
experimentally that seeds of Aristolochia clematitis were commingled with wheat 
seeds and contaminated the flour used by farmers from EN villages (Figure 2). Unlike 
in AAN, where the exogenous carcinogen was present in slimming pills, in EN, 
according to our data, this environmental toxic substance was ingested through bread 
(66,67). Finally, this hypothesis was confirmed by prima facie evidence of the 
presence of AA-DNA adducts in DNA extracted from the renal cortex and from upper 
urinary tract cancer tissue of the patients with EN whom we tested (44). In addition, 
we have reported on the p53 mutations in urothelial tumors of Croatian and Bosnian 
EN patients (44). Using AmpliChip p53 microarray, Exons 2-11 were sequenced and 
19 base substitutions were identified. The mutations at A:T pairs accounted for 89% 
(17/19) of all mutations, with the 78% of these (15/17) being A:T  T:A 
transversions (Figure 3A). Of note, p53 mutations in EN patients with urothelial 
cancers from Croatia and Bosnia are unique and not consistent with IARC p53 
database R12, November 2007 (6). Namely, in other parts of the world (in the general 
population of patients with upper urothelial cancers) the A  T transition account for 
only 4% of all p53 mutations (Figure 3B). In addition, p53 mutations in the patients 
whom we tested appear to cluster between amino acid residues 270 and 290 and at 
four sites mutations occurred twice (179-2, 274-3, 280-3, and 291-1). The 209-1 and 
280-3, both A:T  T:A mutations found in EN patients, were also detected in human 
Hupki cells treated with AAI (49,51).  
 
Conclusion 
Epidemiological, pathological, clinical and biochemical studies confirm that AA is a 
major risk factor for EN. The presence of covalently bound AA-DNA adducts is a 
strong biomarker of prior exposure to this environmental carcinogen. Clinical and 
pathological features of EN and AAN, coupled with characteristic p53 mutational 
spectra in the upper urinary tract malignancies found in this population (the presence 
of AT → TA transversion) are strong supplementary arguments in favor of an 
etiological role of AA in EN-associated urothelial tumors and allow us to suggest that 
EN, CHN and AAN are the same disease and an already acknowledged worldwide 
problem (69) 
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Figure legend: 
 
 
Figure 1. Formation of AA-derived DNA adducts (AAI (R=OCH3) and AAII (R=H). 
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Figure 2. Aristolochia clematitis growing in the middle of wheat field in the Croatian 
endemic village of Kaniža during harvest time 2008.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. p53 mutational spectra in upper urinary tract urothelial cancers (UUC). (A) 
UUC of EN patients in Croatia (19 mutations). (B) Urothelial cancers of kidney, renal 
pelvis, ureter and urethra, excluding bladder (230 mutations). Data from IARC p53 
database, R12 released in November 2007 (6); adapted from ref. 44. 
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